Aevi Genomic Medicine Inc. (GNMX) and Precision BioSciences Inc. (NASDAQ:DTIL) Contrasting side by side

As Biotechnology businesses, Aevi Genomic Medicine Inc. (NASDAQ:GNMX) and Precision BioSciences Inc. (NASDAQ:DTIL), are affected by contrast. This especially applies to their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aevi Genomic Medicine Inc. N/A 0.00 54.95M -0.43 0.00
Precision BioSciences Inc. 9 0.00 36.71M -1.39 0.00

Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.


Table 2 shows us Aevi Genomic Medicine Inc. and Precision BioSciences Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Aevi Genomic Medicine Inc. 43,131,868,131.87% -264.5% -178.4%
Precision BioSciences Inc. 391,364,605.54% 0% 0%


Aevi Genomic Medicine Inc. has a Current Ratio of 1.9 and a Quick Ratio of 1.9. Competitively, Precision BioSciences Inc.’s Current Ratio is 1.9 and has 1.9 Quick Ratio. ‘s better ability to pay short and long-term obligations than .

Institutional & Insider Ownership

Institutional investors owned 6.4% of Aevi Genomic Medicine Inc. shares and 41.6% of Precision BioSciences Inc. shares. About 42.43% of Aevi Genomic Medicine Inc.’s share are owned by insiders. Competitively, Precision BioSciences Inc. has 19.3% of it’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aevi Genomic Medicine Inc. -9.48% -7.97% -32.82% -17.4% -83.14% -76.4%
Precision BioSciences Inc. -0.62% -0.85% -0.54% 0% 0% -26.2%

For the past year Precision BioSciences Inc. has weaker performance than Aevi Genomic Medicine Inc.

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohnÂ’s disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.